CureVac N.V. (FRA:5CV)
Germany flag Germany · Delayed Price · Currency is EUR
3.870
-0.080 (-2.03%)
Jun 5, 2025, 6:47 PM CET
4.03%
Market Cap 875.04M
Revenue (ttm) 523.70M
Net Income (ttm) 180.66M
Shares Out n/a
EPS (ttm) 0.80
PE Ratio 4.84
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 16,339
Average Volume 60,565
Open 3.830
Previous Close 3.950
Day's Range 3.750 - 3.990
52-Week Range 2.170 - 4.950
Beta n/a
RSI 58.70
Earnings Date Aug 15, 2025

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company’s portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In ad... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 983
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 5CV
Full Company Profile

Financial Performance

Financial Statements

News

CureVac BV reports Q1 results

16 days ago - Seeking Alpha

CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates

U.S. FDA clears lung cancer IND for CVHNLC, a proprietary off-the-shelf candidate targeting squamous non-small cell lung cancer (sqNCLC), with clinical study expected to begin H2 2025; Clinical Trial ...

16 days ago - Wallstreet:Online

CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates

U.S. FDA clears lung cancer IND for CVHNLC, a proprietary off-the-shelf candidate targeting squamous non-small cell lung cancer (sqNCLC), with clinical study expected to begin H2 2025; Clinical Trial ...

16 days ago - Accesswire

CureVac Unveils Q1 2025 Financial Results & Business Updates!

CureVac is forging ahead with innovative clinical trials and strategic patent victories, positioning itself for a promising future in the biotech industry. Jetzt den vollständigen Artikel lesen

16 days ago - Wallstreet:Online

EQS-News: CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates

Issuer: CureVac / Key word(s): Quarter Results CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates 20.05.2025 / 13:00 CET/CEST The issuer is solely responsi...

16 days ago - Wallstreet:Online

CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE

European Patent Office largely dismisses opposition filed by BioNTech SE, Pfizer Inc., and others in December 2023 challenging validity of EP 4 023 755 B1 and maintains the patent subject to amendment...

20 days ago - Wallstreet:Online

CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE

European Patent Office largely dismisses opposition filed by BioNTech SE, Pfizer Inc., and others in December 2023 challenging validity of EP 4 023 755 B1 and maintains the patent subject to amendment...

20 days ago - Accesswire

BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion

BioNTech SE (NASDAQ: BNTX) on Monday reported a first-quarter per-share loss of $1.82 (1.73 euros), up from 1.31 euros reported a year ago compared to beating the consensus of $2.02 . The COVID-19 va...

4 weeks ago - Benzinga

CureVac BV reports Q4 results

2 months ago - Seeking Alpha

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate TransformationCompleted enrollment of Part B of Phase 1 glioblastoma study with investigational precisio...

2 months ago - Wallstreet:Online

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate Transformation Completed enrollment of Part B of Phase 1 glioblastoma study with investigational precisi...

2 months ago - Accesswire

CureVac: 2024 Financial Results & Business Update Unveiled

CureVac is making strides in medical innovation, with promising studies and robust financial growth marking a transformative year. Jetzt den vollständigen Artikel lesen

2 months ago - Wallstreet:Online

EQS-News: CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

Issuer: CureVac / Key word(s): Annual Results CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update 10.04.2025 / 13:12 CET/CEST The issuer is solel...

2 months ago - Wallstreet:Online

Earnings Scheduled For April 10, 2025

Companies Reporting Before The Bell • CureVac (NASDAQ: CVAC) is likely to report quarterly loss at $0.09 per share on revenue of $20.58 million. • CarMax (NYSE: KMX) is projected to report quarterly...

2 months ago - Benzinga

Insights Ahead: CureVac's Quarterly Earnings

CureVac (NASDAQ: CVAC) is set to give its latest quarterly earnings report on Thursday, 2025-04-10. Here's what investors need to know before the announcement. Analysts estimate that CureVac will rep...

2 months ago - Benzinga

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

TÜBINGEN, DE / ACCESS Newswire / April 8, 2025 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid...

2 months ago - Wallstreet:Online

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

TÜBINGEN, DE / ACCESS Newswire / April 8, 2025 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid...

2 months ago - Accesswire

CureVac's 2024 Financial Results & Key Updates: April 10 Reveal

Discover CureVac's 2024 financial insights on April 10, 2025, as the mRNA pioneer shares its global achievements and future outlook. Jetzt den vollständigen Artikel lesen

2 months ago - Wallstreet:Online

EQS-News: CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

Issuer: CureVac / Key word(s): Annual Results CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 08.04.2025 / 13:00 CET/CEST The issuer is sole...

2 months ago - Wallstreet:Online

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

Significant Regulatory Milestone: U.S. FDA cleared IND application for CVHNLC, CureVac's investigational therapy targeting squamous non-small cell lung cancerProprietary Epitopes: CVHNLC encodes novel...

2 months ago - Wallstreet:Online

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

Significant Regulatory Milestone: U.S. FDA cleared IND application for CVHNLC, CureVac's investigational therapy targeting squamous non-small cell lung cancer Proprietary Epitopes: CVHNLC encodes nove...

2 months ago - Accesswire

EQS-News: CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

Issuer: CureVac / Key word(s): Study/Regulatory Approval CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small C...

2 months ago - Wallstreet:Online